Durvalumab is a high-affinity humanized IgG1 monoclonal antibody targeting PD-L1 that blocks the binding of PD-L1 to PD-1 and CD80/B7.1, restores the immune response, and kills tumor cells (Chen et al., 2022). Here, PDCD1 is linked to neoplasm.